Biotech Products Services & Research Inc (OTCMKTS:BPSR), which at present, is working on amniotic allograft biological product or New Amnio Product, recently announced that Anu Life Sciences Inc., its subsidiary has winded up the trial production runs for it.

A newly designed product for the health care industry

According to Biotech Products Services & Research Inc, this New Amnio Product is said to be the first of its kind amniotic-based biologics product meant for the health care sector. The company hopes to develop and manufacture this product for commercial supply to this sector.

The company hopes that the product will of great use to hospitals, clinics, doctors and physicians. With this announcement, the company is following its aspiration of emerging as the leading producer and supplier of newly designed products and services based on advanced biologically processed cellular and tissue. The company hopes to commercialize the product so as to meet the growing demand of regenerative medicine healthcare field.

Commercial partner of New Amnio Product

Biotech Products Services & Research Inc believes that its wholly owned subsidiary, Anu Life Sciences Inc. will play a vital role in commercialization this product. The product shall start being available in the commercial platform in the first quarter of 2017.

It is important to note that the trial production runs of New Amnio Product are a chain action of earlier announcement of the company, where it had made a few vital executive changes. These included hiring of a new Chief Operating Officer, Chief Financial Officer, Chief Science Officer and Chief Executive Officer.

The new management team of the company is said to be providing its knowledge and specialization in the fields of finance, technicalities and industry, at large.

The product commercialization would therefore, prove to be an immense success of the new executive changes of this company. Prior to the development of products, the primary revenue sources of Biotech Products Services & Research Inc have been products’ sales and patient referral fee.

Previous articleWhat Is Giving High Tide To Mountain High Acquisitions Corp (OTCMKTS:MYHI) Stock?
Next articleBioelectronics Corp (OTCMKTS:BIEL) Gears Up To Success Of Actipatch® Therapy Device
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.